European Investor
28 Aug 2026, 16:43
FDA Approves Lilly’s Mounjaro to Reduce Cardiovascular Risk in Type 2 Diabetes
Eli Lilly (NYSE: LLY) received U.S. FDA approval for Mounjaro (tirzepatide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk, significantly expanding the drug’s clinical profile beyond blood-sugar control.
The new indication covers cardiovascular death, non-fatal heart attack and non-fatal stroke. Lilly said Mounjaro is now the first and only GIP/GLP-1 receptor agonist proven to lower these cardiovascular risks in high-risk adults with type 2 diabetes, alongside its established A1C and weight-loss benefits.
Approval was based on the large SURPASS-CVOT Phase 3 trial involving more than 13,000 patients. Mounjaro demonstrated non-inferiority to Lilly’s Trulicity, an established GLP-1 therapy with cardiovascular benefits, and recorded an 8% lower rate of cardiovascular death, heart attack or stroke. However, statistical superiority over Trulicity was not established.
The approval is commercially important for Lilly because it strengthens Mounjaro’s competitive position in the rapidly expanding incretin market. Cardiovascular benefits have become an increasingly important differentiator for GLP-1-based medicines, and the broader label could support greater adoption of Mounjaro among high-risk diabetes patients.
Eli Lilly (NYSE: LLY) received U.S. FDA approval for Mounjaro (tirzepatide) to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk, significantly expanding the drug’s clinical profile beyond blood-sugar control.
The new indication covers cardiovascular death, non-fatal heart attack and non-fatal stroke. Lilly said Mounjaro is now the first and only GIP/GLP-1 receptor agonist proven to lower these cardiovascular risks in high-risk adults with type 2 diabetes, alongside its established A1C and weight-loss benefits.
Approval was based on the large SURPASS-CVOT Phase 3 trial involving more than 13,000 patients. Mounjaro demonstrated non-inferiority to Lilly’s Trulicity, an established GLP-1 therapy with cardiovascular benefits, and recorded an 8% lower rate of cardiovascular death, heart attack or stroke. However, statistical superiority over Trulicity was not established.
The approval is commercially important for Lilly because it strengthens Mounjaro’s competitive position in the rapidly expanding incretin market. Cardiovascular benefits have become an increasingly important differentiator for GLP-1-based medicines, and the broader label could support greater adoption of Mounjaro among high-risk diabetes patients.
